Effects of fidaxomicin: A Synthesis of Findings from 13 Studies

  1. Home
  2. Effects of fidaxomicin
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of fidaxomicin: A Synthesis of Findings from 13 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of fidaxomicin: A Synthesis of Findings from 13 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Fidaxomicin has been shown to be effective in treating Clostridioides difficile infection (CDI) in multiple studies. 6 7 Fidaxomicin has been reported to have lower recurrence rates compared to vancomycin. 6 However, a study comparing fidaxomicin and oral metronidazole found that fidaxomicin had a higher clinical cure rate and a lower recurrence rate, although not statistically significant. 7 Fidaxomicin was also found to be effective in patients with macrolide allergy/intolerance. Furthermore, fidaxomicin has been shown to suppress Clostridium difficile spores in an in-vitro gut model. 1 Fidaxomicin is thought to bind to Clostridium difficile spores, inhibiting spore growth. 1 In contrast, vancomycin did not show any effect on suppressing Clostridium difficile spores. 1 These findings suggest that fidaxomicin could be effective not only in treating Clostridium difficile infection but also in preventing recurrence.

Benefits and Risks

Benefits Summary

Fidaxomicin has been shown to be effective in treating Clostridioides difficile infection (CDI). 6 7 Fidaxomicin has been reported to have lower recurrence rates compared to vancomycin. 6 Fidaxomicin was also found to be effective in patients with macrolide allergy/intolerance. Fidaxomicin has been shown to suppress Clostridium difficile spores in an in-vitro gut model. 1

Risks Summary

Fidaxomicin is generally considered safe, but side effects can occur in rare cases. Side effects may include diarrhea, abdominal pain, nausea, vomiting, rash, and itching. 8 Fidaxomicin should be used with caution in patients with impaired kidney or liver function. 8

Comparison Between Studies

Similarities

Many studies have shown that fidaxomicin is effective in treating Clostridioides difficile infection (CDI). 6 7 1 Fidaxomicin has been reported to have lower recurrence rates compared to vancomycin. 6 Furthermore, fidaxomicin has been shown to suppress Clostridium difficile spores. 1

Differences

A study comparing fidaxomicin and oral metronidazole found that fidaxomicin had a higher clinical cure rate and a lower recurrence rate, although not statistically significant. 7

Consistency and Contradictions of Results

There is consistency in the results of many studies showing the effectiveness of fidaxomicin in treating Clostridioides difficile infection (CDI). 6 7 1 However, contradictions can be observed in the results of the comparison studies between fidaxomicin and oral metronidazole. 7 Further research is needed to address these inconsistencies.

Considerations for Real-Life Applications

While fidaxomicin is an effective drug for treating Clostridioides difficile infection (CDI), it does not work for all patients. 8 Fidaxomicin should be used with caution in patients with impaired kidney or liver function. 8 It is important to consult with your doctor before taking fidaxomicin.

Limitations of Current Research

The research on the effectiveness of fidaxomicin is not yet complete. 8 In particular, comparative studies between fidaxomicin and other treatment methods are not yet comprehensive. 8 Additionally, research on the long-term safety of fidaxomicin is still ongoing. 8

Future Research Directions

Further research is needed to better understand the effectiveness and safety of fidaxomicin. 8 In particular, comparative studies between fidaxomicin and other treatment methods and research on the long-term safety of fidaxomicin are required. 8

Conclusion

Fidaxomicin is an effective drug for treating Clostridioides difficile infection (CDI). 6 7 1 Fidaxomicin has been reported to have lower recurrence rates compared to vancomycin. 6 However, fidaxomicin does not work for all patients. 8 It is important to consult with your doctor before taking fidaxomicin. 8

Literature analysis of 13 papers
Positive Content
9
Neutral Content
1
Negative Content
2
Article Type
0
0
0
5
12
2.

Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea.

Author: WeissKarl, LouieThomas, MillerMark A, MullaneKathleen, CrookDerrick W, GorbachSherwood L

CDAD risk

This study investigated the effects of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) on clinical response and recurrence rates of Clostridium difficile-associated diarrhoea (CDAD).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

5.

Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient.

Author: Lo PortoDavide, MularoniAlessandra, CastagnolaElio, SaffiotiCarolina

CDI management
Reduced recurrence risk

Clostridioides difficile infection (CDI) is a serious complication in patients who undergo hematopoietic cell transplantation. This review discusses the diagnosis and treatment of CDI in this population.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis.

Author: StabholzYoav, PaulMical

CDI treatment
Lower recurrence rates
Mortality
Recurrences

This article discusses the current guidelines for treating Clostridioides difficile infection (CDI), a common gastrointestinal infection. The article highlights the preference for fidaxomicin over vancomycin and the exclusion of metronidazole from the recommended treatment regimen.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Therapeutics for <i>Clostridioides difficile</i> infection: molecules and microbes.

Author: KhannaSahil, VothElida

यो लेखले क्लोस्ट्रिडियोइड्स डिफिसाइल संक्रमण (CDI) को व्यवस्थापनमा भएका केही प्रगतिको समीक्षा गर्छ।

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

Clostridioides difficile Infection in Children: Recent Updates on Epidemiology, Diagnosis, Therapy.

Author: ShirleyDebbie-Ann, TornelWilliam, WarrenCirle A, MoonahShannon

CDI treatment
FMT for recurrent CDI

Clostridioides difficile infection (CDI) is a significant concern in children, with increasing incidence and a spectrum of severity. While metronidazole remains a mainstay therapy, oral vancomycin and fidaxomicin are emerging alternatives, and fecal microbiota transplantation is gaining traction for recurrent CDI. This review highlights the unique challenges and advancements in managing CDI in children.

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

10.

An insight into <i>Clostridioides difficile</i>-associated diarrhea in Saudi children: diagnosis and treatment.

Author: ThabitAbrar K, AljedaaniHuda J, AlghamdiRawan H, BadahdahRaghad M, LashkarManar O, AlnajjarAbeer

Antibiotic-associated diarrhea

This study examines the diagnosis and treatment of pediatric Clostridioides difficile infection (CDI) in Saudi Arabia. The study found that the practice in Saudi Arabia differs slightly from international guidelines.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

A Case of Oral-Vancomycin-Induced Rash in a Patient with Acute Kidney Injury.

Author: CardozoMilena, ParmarAngadbir S, Rueda PradaLibardo, ShwetaFnu

Allergic reaction
Vancomycin side effects

This case study describes a 66-year-old patient with severe Clostridioides difficile infection (CDI) and acute renal failure who developed a suspected Vancomycin-induced allergic reaction.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

12.

Predicted Bezlotoxumab Exposure in Patients Who Have Received a Hematopoietic Stem Cell Transplant.

Author: de AlmeidaCamila, WongMichael, KleijnHuub Jan, WrishkoRebecca E

CDI prevention

Bezlotoxumab is used to prevent recurrent Clostridioides difficile infection (CDI). This study examines whether patients undergoing hematopoietic stem cell transplant (HSCT), who have decreased albumin levels, are at risk of reduced bezlotoxumab exposure.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.